FDA Ups Foreign Inspections In Fiscal 07; Visits 11% Of Establishments
This article was originally published in The Tan Sheet
Executive Summary
Data from a Government Accountability Office report suggest FDA took to heart criticism of its procedures for inspecting foreign drug manufacturers, but is struggling to improve performance given financial pressures
You may also be interested in...
Enhanced FDA Oversight Added To GAO’s “High Risk” List
The Government Accountability Office has added enhanced oversight of devices, drugs and other medical products to its list of "high risk" priorities
Enhanced FDA Oversight Added To GAO’s “High Risk” List
The Government Accountability Office has added enhanced oversight of devices, drugs and other medical products to its list of "high risk" priorities
Enhanced FDA Oversight Added To GAO’s “High Risk” List
The Government Accountability Office has added enhanced oversight of devices, drugs and other medical products to its list of "high risk" priorities